Giredestrant Outperforms SOC in ER+/HER2- Early Breast Cancer

At the San Antonio Breast Cancer Symposium, Aditya Bardia, MD, MPH, FASCO, professor in the Department of Medicine, Division of Hematology/Oncology and director of Translational Research Integration at UCLA Health, discussed results from the phase 3 lidERA trial (NCT04961996) comparing giredestrant (GDC-9545) with standard-of-care endocrine therapy in patients with estrogen receptor–positive, HER2‑negative, medium- and high‑risk early breast cancer.

Bardia reported that giredestrant significantly improved invasive disease‑free survival (IDFS). Three‑year IDFS rates were 92.4% for giredestrant versus 89.6% for standard‑of‑care endocrine therapy.

The benefit was consistent across all prespecified subgroups, including premenopausal patients and those with prior chemotherapy.

Secondary endpoints also favored giredestrant, with a 31% reduction in risk of distant recurrence (hazard ratio 0.69) and a numerically favorable trend in overall survival (hazard ratio 0.79); overall survival data remain immature.